The implantation of vascular stents is popularly adopted to treat atherosclerotic cardiovascular diseases. Salvianolic acid B (Sal B), a bioactive compound extracted from Salvia miltiorrhiza, has been gradually substantiated for its robust anti-inflammatory properties and its potential to enhance cardiovascular function. Nonetheless, the current state of research predominantly concentrates on addressing cardiovascular diseases through intravenous administration, a method fraught with limitations such as suboptimal drug bioavailability. Based on the current knowledge, the current study employs poly (lactic-co-glycolic acid) (PLGA) as a drug carrier to fabricate Sal B eluting coating (Sal B/PLGA) on the surface of vascular stents. It is designed to achieve localized drug release at the site of the lesion and improve the long-term function of the stent. The work aims to enhance the long-term functionality of the stents, providing an innovative strategy for improving the effectiveness of stent treatments in the future. The Sal B/PLGA coating was meticulously developed on the surface of vascular stents through the utilization of ultrasound-assisted spray coating technology and comprehensively characterized via multiple techniques. The chemical structure, drug release behavior and surface morphology of the coating were characterized via Fourier-transform infrared spectroscopy (FTIR), ultraviolet-visible spectrophotometry (UV-Vis), and field emission scanning electron microscopy (SEM), respectively. In vitro cellular experiments were conducted to evaluate the impact of the coating on the proliferation of endothelial cells (ECs) and smooth muscle cells (SMCs), as well as its anti-inflammatory ability. In the final phase of the research, the blood compatibility and anti-thrombotic properties of the coating were validated through in vitro blood compatibility assays. Furthermore, ex vivo blood circulation experiments were performed to provide a more realistic assessment of the coating performance in a physiological context. Material characterization results indicated the successful construction of the Sal B/PLGA coating on the vascular stent. The coating exhibited favorable mechanical properties, allowing it to withstand deformation caused by stent expansion, and ensured efficient release of Sal B for over 28 days. The results of cell biology indicated that the coating had anti-inflammatory effects. It not only promoted the functionality of endothelial cells, but also concurrently restrained the abnormal proliferation of smooth muscle cells. Furthermore, insights from blood compatibility and ex vivo circulation experiments indicated the notable ability of the coating to reduce platelet adhesion, aggregation, and activation. These findings affirm its anti-thrombotic functionality, effectively reducing the risk of post-stent implantation coagulation. The Sal B/PLGA vascular stent coating shows promising attributes, encompassing anti-inflammatory, endothelial-promoting, inhibition of smooth muscle proliferation, and anti-thrombotic properties. This array of characteristics introduces an innovative strategy with the potential to significantly enhance the efficacy of stent treatments in the future.